Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
Status:
Completed
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
A multi-center , opened, Phase II study to assess the efficacy and safety of Sulfatinib 300
mg Sulfatinib in advanced Medullary Thyroid Carcinoma ( MTC) and iodine-refractory
differentiated thyroid carcinoma (DTC).